pocketful logo light
pocketful logo light
Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE BSE: 532321

₹1070.80

(0.34%)

Sat, 20 Jun 2026, 03:15 pm

mtf coin illustrationMTF 5x

Zydus Lifesciences Share Price Live Chart

1 Day

(0.34%)

No Result Found

Summary

  • Market Cap (in Cr)

    108441.84

  • Net Profit (in Cr)

    4614.8

  • P/B

    3.72

  • Sector P/E

    33.76

  • P/E

    19.69

  • EV/EBITDA

    12.57

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    21.08

  • ROCE

    24.56

  • Debt/Equity

    0.09

  • EPS (TTM)

    53.99

  • Dividend Yield

    0.09

  • Book Value

    269.43

  • Interest Cover

    37.33

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters75.0075.0074.9974.9974.99
FII6.957.067.347.137.32
DII11.2011.0910.8611.1311.01
Public6.856.856.806.746.68
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

55.72

MACD

22.22

50 DMA

999.48

200 DMA

954.52

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1473.481251.131164.421028.78942.07806.43584.08
Fibonacci1251.131166.201113.721028.78943.85891.37806.43
Camarilla1138.851118.461098.081028.781057.321036.941016.55

Pivots Level: Classic

R3

+444.70

1473.48

R2

+222.35

1251.13

R1

+135.63

1164.42

1028.78
1028.78
Pivot Point
LTP: 1070.80

S1

-86.72

942.07

S2

-222.35

806.43

S3

-444.70

584.08

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1079.42

  • 20-EMA

    1067.38

  • 30-EMA

    1048.81

  • 50-EMA

    1017.70

  • 100-EMA

    979.66

  • 200-EMA

    960.80

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
19 May 2026board-meetingsQuarterly Results, Final Dividend
19 May 2026agm
19 May 2026buyback
19 May 2026dividend₹1.00 Dividend /Share24 Jul 2026
09 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
25 Jun 2025dividendFinal Dividend - Rs. - 1125 Jul 2025
20 May 2025agm
19 May 2025dividend₹11.00 Dividend /Share25 Jul 2025
26 Jun 2024dividendFinal Dividend - Rs. - 326 Jul 2024

Read More

Peer Comparison

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Zydus Lifesciences Ltd About

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

Pankaj R Patel

Employees

Contact

Website icon

Website

http://www.zyduscadila.com

Email icon

Email

dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.

Phone icon

Phone

91-079-26868100

Location icon

Location

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Read More

Zydus Lifesciences Ltd Company History

YearHistory
2020
  • Zydus and CMS entered pact for Desidustat in Greater China.
  • Zydus Wellness launched hand sanitizer under Nycil brand.
  • Zydus Cadila launched COVID-19 drug Remdesivir in India.
  • Zydus Cadila launched new product for COPD patients in India.
2021
  • Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
  • Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
  • Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
  • Zydus Group had 338 approvals and filed over 431 ANDAs.
  • Zydus Life received final USFDA approval for Topiramate extended-release capsules.
  • Zydus Lifesciences' arm received EC approval for MoCD injection.
  • Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
  • Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
  • Zydus Lifesciences received USFDA approval for Acyclovir Cream.
  • Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
  • Zydus Lifesciences received 7th CSR Health Impact Award.
2024
  • Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
  • Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
UBS PRINCIPAL CAPITAL ASIA LIMITEDbulkSell67016641128.1130 Aug 2024
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.bulkBuy5460159258.2128 May 2019
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFbulkSell555000402.7930 Nov 2015
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFbulkBuy710279740330 Nov 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell4604326427.7527 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy4604326427.7527 Oct 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell2169720435.520 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy2169720435.520 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy155983942414 Oct 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell155983942414 Oct 2015

Read More

Zydus Lifesciences Ltd News

Zydus completes ₹1,100 crore buyback

Zydus Lifesciences concluded its ₹1,100 crore share buyback, accepting 87.30 lakh shares at ₹1,260 each. The tender offer saw a subscription of 93.61 times.

18 Jun 2026

companies

Zydus completes Assertio acquisition

Zydus Lifesciences acquired 66.32% of Assertio Holdings at $23.50 per share. The merger completes on June 16, 2026.

16 Jun 2026

companies

Zydus Lifesciences Gets USFDA Warning Letter for Baddi Facility

Zydus Lifesciences received a USFDA warning letter for its Baddi facility over purified talc not meeting USP standards; current operations and supplies remain unaffected.

03 Jun 2026

companies

Zydus Lifesciences Gets US FDA Priority Review for Saroglitazar NDA

Zydus Lifesciences has received US FDA Priority Review for its New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC).

27 May 2026

companies

Zydus Lifesciences discloses share transmission

Zydus Lifesciences disclosed the transmission of 10,000 equity shares from a deceased promoter group member to Mr. Samar Babubhai Patel. The transaction was off-market and intimated to the company on May 25, 2026.

26 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number